365 related articles for article (PubMed ID: 22173588)
1. Challenges ahead for companion diagnostics.
Schmidt C
J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588
[No Abstract] [Full Text] [Related]
2. Early accelerated approval for highly targeted cancer drugs.
Chabner BA
N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
[No Abstract] [Full Text] [Related]
3. FDA approves vemurafenib for treatment of metastatic melanoma.
Oncology (Williston Park); 2011 Sep; 25(10):906. PubMed ID: 22010387
[No Abstract] [Full Text] [Related]
4. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
5. Larger companies dominate cancer companion diagnostic approvals.
Schmidt C
Nat Biotechnol; 2011 Nov; 29(11):955-7. PubMed ID: 22068512
[No Abstract] [Full Text] [Related]
6. Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.
Technol Eval Cent Assess Program Exec Summ; 2011 Nov; 26(7):1-5. PubMed ID: 22724160
[No Abstract] [Full Text] [Related]
7. Drug approvals 2011: focus on companion diagnostics.
Goozner M
J Natl Cancer Inst; 2012 Jan; 104(2):84-6. PubMed ID: 22215850
[No Abstract] [Full Text] [Related]
8. More Than One Way to Measure? A Casuistic Approach to Cancer Clinical Trials.
Andreoletti M
Perspect Biol Med; 2018; 61(2):174-190. PubMed ID: 30146517
[TBL] [Abstract][Full Text] [Related]
9. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
10. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
11. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.
Ocana A; Ethier JL; Díez-González L; Corrales-Sánchez V; Srikanthan A; Gascón-Escribano MJ; Templeton AJ; Vera-Badillo F; Seruga B; Niraula S; Pandiella A; Amir E
Oncotarget; 2015 Nov; 6(37):39538-49. PubMed ID: 26446908
[TBL] [Abstract][Full Text] [Related]
12. American Society of Clinical Oncology Developing First Clinical Trial.
Brower V
J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
[No Abstract] [Full Text] [Related]
13. FDA approves new melanoma treatments.
Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):3. PubMed ID: 22396993
[No Abstract] [Full Text] [Related]
14. From genome to drugs: where do we stand?
Schmidt C
J Natl Cancer Inst; 2011 Jul; 103(13):996-7. PubMed ID: 21693728
[No Abstract] [Full Text] [Related]
15. Targeted products yield most promising results.
Klem J; Mehr SR; Pestil Zimmerman M
Am J Manag Care; 2012 Feb; 18(1 Spec No.):SP15-8. PubMed ID: 22468867
[No Abstract] [Full Text] [Related]
16. Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it.
Printz C
Cancer; 2015 May; 121(10):1529-30. PubMed ID: 25946212
[No Abstract] [Full Text] [Related]
17. 'Basket studies' will hold intricate data for cancer drug approvals.
Willyard C
Nat Med; 2013 Jun; 19(6):655. PubMed ID: 23744135
[No Abstract] [Full Text] [Related]
18. A Precision Medicine Approach to Clinical Trials.
Rubin R
JAMA; 2016 Nov; 316(19):1953-1955. PubMed ID: 27760248
[No Abstract] [Full Text] [Related]
19. Drugs, diagnostic tests approved quickly.
Rose S
Cancer Discov; 2011 Oct; 1(5):371. PubMed ID: 22586620
[TBL] [Abstract][Full Text] [Related]
20. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
